Iron Supplementation and Intestinal Health

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

183 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-17

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized double-blinded study of enteral iron supplementation in Very Low Birth Weight infants. The subjects will be randomized into low dose (2 mg/kg/day) and high dose (6 mg/kg/day) of daily iron supplementation. The primary outcomes are intestinal health including microbiome, inflammation, and barrier function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Iron Exposure on the Gut Microbiota in Young Infants

NCT03828708

Infant Development

UNKNOWN NA

Feeding Bovine Colostrum to Preterm Infants

NCT02054091

Feeding Intolerance Extrauterine Growth Retardation Necrotizing Enterocolitis +2 more

COMPLETED NA

Alteration of Stool Microbiota in Preterm Infants With Anemia

NCT03554278

Anemia, Neonatal Necrotizing Enterocolitis Dysbiosis

COMPLETED

Preterm Infants Fed a Human Milk Fortifier

NCT05551975

Growth

NOT_YET_RECRUITING NA

Bovine Colostrum as a Human Milk Fortifier for Preterm Infants

NCT03822104

Feeding Intolerance Necrotizing Enterocolitis Postnatal Growth +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Infants and mothers will be recruited at a single academic level III NICU at Tampa General Hospital, Tampa, FL. Inclusion criteria infants: \<1500 g at birth, expected to live beyond 2 weeks, not yet started on oral iron supplementation (OIS), and parental consent. Exclusion criteria infants: congenital intestinal defects, history of intestinal infection or perforation before OIS. Infants who require epogen for religious reason to prevent them from getting blood transfusions will be excluded from the study.

Intervention: Participants will be randomized to either 6 mg/kg/day or 2 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study OIS doses until 36 week corrected gestational age or discharge, whichever comes first.

Sample collection and testing:

1. Stool and urine collection: We will collect weekly stool and urine samples non-invasively starting at enrollment until study completion. Samples will be collected from soiled diapers.
2. Blood tests: We will collect C-reactive protein (CRP) and ferritin level at 4 weeks after birth at the same time as other routine labs (complete blood count, reticulocyte count, and liver function test).
3. Monaural auditory brainstem response (ABR): for each ear will be performed at 36 weeks corrected gestational age or at discharge under the supervision of an audiologist who is blinded to the infants assigned iron doses and test results (stool microbiome, blood and urine tests).

Monitoring: iron supplementation dose will be increased by 2 mg/kg/day if ferritin level \<100 mg/dL and the dose will be held if ferritin level \>400 mg/dL. Ferritin level will be rechecked every 2 weeks until normalized. Hematocrit and reticulocyte count will be monitored by the medical team.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia of Prematurity Very Low Birth Weight Infant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomize subjects to low and high dose iron supplementations

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

The participants, care givers, medical teams, investigator, and outcome assessors are blinded from the iron treatment dose for the duration of the study. Only research pharmacists and members of the Data and Safety Monitor Board are unblinded during the study period.

In an event when the medical team urgently needs to know the iron dose the participant is receiving for proper clinical management of the subject, the principal investigator or a designee will be notified by cell phone. Their contact information are located in the medical workrooms and the unit pharmacy. The principal investigator or the designee will immediately call the research pharmacy phone to request an emergency unblinding of that particular participant. The principal investigator will inform IRB and the sponsor of the unblinding event within 24 hours.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low Iron Sulfate Supplementation

Participants will be given 2 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.

Group Type ACTIVE_COMPARATOR

2mg/kg/day Iron Sulfate

Intervention Type DRUG

Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.

High Iron Sulfate Supplementation

Participants will be given 6 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.

Group Type ACTIVE_COMPARATOR

6 mg/kg/day Iron Sulfate

Intervention Type DRUG

Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

2mg/kg/day Iron Sulfate

Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.

Intervention Type DRUG

6 mg/kg/day Iron Sulfate

Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Low dose iron supplementation High dose iron supplementation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \<1500 g at birth, expected to live beyond 2 weeks, not yet started on oral iron supplementation (OIS), with mother at least 18 years of age, and parental consent.

Exclusion Criteria

* congenital intestinal defects, history of intestinal infection or perforation before OIS. Infants who require epogen for religious reason to prevent them from getting blood transfusions will be excluded from the study.

Minimum Eligible Age

1 Day

Maximum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes